Greetings from MyCancerHaven!
We wanted to update you on our recent activities.
Here are the latest posts last week:
Blogs :
Navigating ESA failure in myelodysplastic syndromes and exploring alternative treatments.
Noteworthy developments in 2024 breaking ground in myelodysplastic syndromes (MDS).
Expert perspectives on ESA treatment outcomes in lower-risk myelodysplastic syndromes.
Key takeaways from the COMMANDS trial for optimizing MDS management strategies.
Esther Olivia reports COMMANDS trial HRQoL results unveiled at ASH 2024.
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
We wanted to update you on our recent activities.
Here are the latest posts last week:
Blogs :
Navigating ESA failure in myelodysplastic syndromes and exploring alternative treatments.
Noteworthy developments in 2024 breaking ground in myelodysplastic syndromes (MDS).
Expert perspectives on ESA treatment outcomes in lower-risk myelodysplastic syndromes.
Key takeaways from the COMMANDS trial for optimizing MDS management strategies.
Esther Olivia reports COMMANDS trial HRQoL results unveiled at ASH 2024.
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
